Caxton Associates LP Denali Therapeutics Inc. Transaction History

Caxton Associates LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$17.99 - $24.65 $2.41 Million - $3.3 Million	-134,047 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$13.88 - $21.75 $416,400 - $652,500	30,000 Added 28.83%	134,047 $2.77 Million
Q3 2018 Nov 14, 2018	BUY	$12.46 - $21.74 $1.3 Million - $2.26 Million	104,047 New	104,047 $2.26 Million

228

120M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.27B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.